Form 4: Imunon Executive Chairman Acquires Stock Options

Michael H. Tardugno, Executive Chairman of Imunon, Inc., acquired stock options exercisable for 12,500 shares of common stock on March 15, 2024.

Summary

• On March 15, 2024, Michael H. Tardugno, the Executive Chairman of the Board of Imunon, Inc., was granted stock options to purchase 12,500 shares of Imunon's common stock.
• The exercise price of these options is $0.86 per share, which was the closing price of Imunon's common stock on the grant date.
• The options vest in three tranches: 1/2 on the date of grant, 1/4 on the one-year anniversary of the grant date, and 1/4 on the two-year anniversary of the grant date.
• The options expire on March 15, 2034.
• Following this transaction, Mr. Tardugno beneficially owns 228,346 shares of Imunon's common stock directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither particularly positive nor negative.

Positives

• The grant of stock options to the Executive Chairman aligns his interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are generally in line with industry norms for similar-sized companies.

Stakeholder Impact

• The stock option grant could potentially incentivize the Executive Chairman to improve company performance, benefiting shareholders.

Key Dates

Keywords

Imunon, Tardugno, stock options, beneficial ownership, Form 4, IMNN, executive compensation